19.12
+0.65(+3.52%)
Currency In USD
Address
1065 East Hillsdale Boulevard
Foster City, CA 94404
United States of America
Phone
650 525 5535
Website
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Ms. Amy L. Burroughs M.B.A. | Chief Executive Officer & Director | 1.01M | 1971 |
| Ms. Melita Sun Jung | Chief Business Officer | 508,886 | 1977 |
| Dr. Emil T. Kuriakose M.D. | Chief Medical Officer | 0 | 1980 |
| Ms. Yasameen Qazen | Senior Vice President of Regulatory Affairs & Quality Assurance | 0 | N/A |
| Mr. James Kanter | Senior Vice President of CMC | 0 | N/A |
| Mr. David Eric Strauss | Vice President of Finance & Controller | 0 | 1986 |
| Mr. Andrew W. Gengos | Chief Financial Officer | 0 | 1964 |
| Dr. Jeffrey R. Jasper Ph.D. | Senior Vice President of Research | 0 | N/A |
| Mr. Scott Harris | Chief Development Officer | 0 | N/A |
| Ms. Debra Sieminski | Senior Vice President of Medical Affairs | 0 | N/A |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.